[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608151":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":35,"centralContacts":48,"locations":54,"responsibleParty":237,"collaborators":35,"id":239,"slug":240,"hasResults":241,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":35,"eligibilityCriteria":245,"healthyVolunteers":241,"sex":246,"minAge":247,"maxAge":35,"enrollmentInfo":248,"targetDuration":35,"studyType":251,"phases":252,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":74,"whyStopped":35,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},{"fullName":5,"class":6},"MediLink Therapeutics (Suzhou) Co., Ltd.","INDUSTRY",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 and Part 2: Mono Dose Escalation & Expansion","EXPERIMENTAL","Participants receive YL242 administered via intravenous (IV) solution per protocol defined dose level and frequency.",[13],"Drug: YL242",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 3 and 4: Combination Dose Escalation & Expansion","Participants receive YL242 at protocol defined dose level, in combination with Pembrolizumab (200 mg), administered via intravenous (IV) solution at protocol defined dose level and frequency.",[18],"Drug: YL242; Pembrolizumab",{"label":20,"type":10,"description":21,"interventionNames":22},"Part 5: Combination Dose Optimization and Expansion","Participants receive YL242, 5-FU and LV, administered via intravenous (IV) solution.",[23],"Drug: YL242; 5-FU; LV",{"label":25,"type":10,"description":26,"interventionNames":27},"Part 6: Combination Dose Optimization and Expansion","Participants receive YL242, pembrolizumab and 5-FU, administered via intravenous (IV) solution at protocol defined frequency.",[28],"Drug: YL242; Pembrolizumab; 5-FU",[30,36,40,44],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","YL242","The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes.",[9],null,{"type":31,"name":37,"description":38,"armGroupLabels":39,"otherNames":35},"YL242; Pembrolizumab","The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes. Pembrolizumab will be administered subsequent to YL242.",[15],{"type":31,"name":41,"description":42,"armGroupLabels":43,"otherNames":35},"YL242; 5-FU; LV","The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes.\n\nLV and 5-FU will be sequentially administered following YL242.",[20],{"type":31,"name":45,"description":46,"armGroupLabels":47,"otherNames":35},"YL242; Pembrolizumab; 5-FU","The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. YL242 will be administered via Intravenous (IV) Infusion.\n\nPembrolizumab and 5-FU will be administered in sequence after YL242.",[25],[49],{"name":50,"role":51,"phone":52,"phoneExt":35,"email":53},"Medilink Study Team","CONTACT","+86 0512-62858368","clinicaltrials@medilinkthera.com",[55,72,85,97,109,121,133,144,158,165,176,187,199,213,225],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"US-201","NOT_YET_RECRUITING","New Haven","Connecticut","06519","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-72.92816,41.30815,{"lat":67,"lon":66},[70],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},"study coordinator",{"facility":73,"status":74,"city":75,"state":76,"zip":77,"country":61,"countryCode":62,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"US-202","RECRUITING","Sarasota","Florida","34232",{"type":64,"coordinates":79},[80,81],-82.53065,27.33643,{"lat":81,"lon":80},[84],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":86,"status":57,"city":87,"state":88,"zip":89,"country":61,"countryCode":62,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"US-204","Boston","Massachusetts","02215",{"type":64,"coordinates":91},[92,93],-71.05977,42.35843,{"lat":93,"lon":92},[96],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":98,"status":74,"city":99,"state":100,"zip":101,"country":61,"countryCode":62,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"US-206","Grand Rapids","Michigan","49546",{"type":64,"coordinates":103},[104,105],-85.66809,42.96336,{"lat":105,"lon":104},[108],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":110,"status":74,"city":111,"state":112,"zip":113,"country":61,"countryCode":62,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"US-205","Nashville","Tennessee","37203",{"type":64,"coordinates":115},[116,117],-86.78444,36.16589,{"lat":117,"lon":116},[120],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":122,"status":57,"city":123,"state":124,"zip":125,"country":61,"countryCode":62,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"US-203","Houston","Texas","77030",{"type":64,"coordinates":127},[128,129],-95.36327,29.76328,{"lat":129,"lon":128},[132],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":134,"status":57,"city":135,"state":124,"zip":136,"country":61,"countryCode":62,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"US-207","San Antonio","78229",{"type":64,"coordinates":138},[139,140],-98.49363,29.42412,{"lat":140,"lon":139},[143],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":145,"status":57,"city":146,"state":147,"zip":148,"country":149,"countryCode":150,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"AUS-101","Liverpool","New South Wales","2170","Australia","AU",{"type":64,"coordinates":152},[153,154],150.92588,-33.91938,{"lat":154,"lon":153},[157],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":159,"status":74,"city":160,"state":161,"zip":162,"country":149,"countryCode":150,"cosmosGeoPoint":35,"geoPoint":35,"contacts":163},"AUS-102","Darlinghurst","Victoria","2010",[164],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":166,"status":57,"city":167,"state":161,"zip":168,"country":149,"countryCode":150,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"AUS-104","Fitzroy","3065",{"type":64,"coordinates":170},[171,172],144.97833,-37.79839,{"lat":172,"lon":171},[175],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":177,"status":57,"city":178,"state":161,"zip":179,"country":149,"countryCode":150,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"AUS-103","Heidelberg","3084",{"type":64,"coordinates":181},[182,183],145.06667,-37.75,{"lat":183,"lon":182},[186],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":188,"status":57,"city":189,"state":190,"zip":191,"country":149,"countryCode":150,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"AUS-105","Nedlands","Western Australia","6009",{"type":64,"coordinates":193},[194,195],115.8073,-31.98184,{"lat":195,"lon":194},[198],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":200,"status":74,"city":201,"state":202,"zip":203,"country":204,"countryCode":205,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"CN-303","Harbin","Heilongjiang","150081","China","CN",{"type":64,"coordinates":207},[208,209],126.65,45.75,{"lat":209,"lon":208},[212],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":214,"status":74,"city":215,"state":216,"zip":217,"country":204,"countryCode":205,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"CN-301","Shanghai","Shanghai Municipality","200030",{"type":64,"coordinates":219},[220,221],121.45806,31.22222,{"lat":221,"lon":220},[224],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"facility":226,"status":74,"city":227,"state":228,"zip":229,"country":204,"countryCode":205,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"CN-302","Hangzhou","Zhejiang","310022",{"type":64,"coordinates":231},[232,233],120.16142,30.29365,{"lat":233,"lon":232},[236],{"name":71,"role":51,"phone":35,"phoneExt":35,"email":35},{"type":238,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100608151","phase-1-a-study-of-yl242-in-subjects-with-advanced-solid-tumors-100608151",false,"NCT07197827","A Study of YL242 in Subjects With Advanced Solid Tumors","A Phase 1\u002F2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors.","Inclusion Criteria:\n\n* Aged ≥18 years.\n* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1\n* Adequate organ and bone marrow function\n* Tumor type:\n\nPart 1-3: Advanced\u002Funresectable or metastatic solid malignant tumor; Have received at least one prior line of systemic anti-tumor therapy\n\nPart 4: locally advanced or metastatic non-sq NSCLC without AGA and HCC; Have not received any systemic anti-tumor therapy;\n\nPart 5: mCRC, have received at least one (5a) or one (5b) prior line of systemic anti-tumor therapy\n\nPart 6: advanced or metastatic HER2-negative G\u002FGEJ; have received at least one (6a) or one (6b) prior line of systemic anti-tumor therapy\n\nExclusion Criteria:\n\n* Be intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor\n* Uncontrolled or clinically significant cardiovascular and cerebrovascular diseases\n* Clinically significant concomitant pulmonary disease\n* A history of leptomeningeal carcinomatosis or carcinomatous meningitis\n* Any illness, medical condition, organ system dysfunction, or social situation, including but not limited to mental illness or substance\u002Falcohol abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, adversely affect the patient's ability to cooperate and participate in the study, or compromise the interpretation of study results","ALL","18 Years",{"count":249,"type":250},424,"ESTIMATED","INTERVENTIONAL",[253,254],"PHASE1","PHASE2","This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.",[257],"Advanced Solid Tumor",[259,260,261,262],"Oncology","VEGF","Antibody drug conjugate","Developmental Phase I\u002FII","2025-12-23",{"date":265,"type":266},"2025-12-24","ACTUAL",{"date":268,"type":266},"2025-09-22",{"date":270,"type":250},"2028-11",{"name":5,"class":6},15]